Introduction {#sec1-1}
============

In absence of a cure, the human immunodeficiency virus (HIV) still remains one of the greatest public health challenges in the 21^st^ Century with sub-Saharan Africa suffering most of the brunt of the HIV epidemic. However over the past decade, there has been tremendous improvement in the quality of life for persons living with HIV/AIDS (PLHA) in sub-Saharan Africa due to the introduction and expansion of highly active antiretroviral therapy (HAART).^[@ref1]^ Many studies from sub-Saharan Africa, have highlighted the critical role of antiretroviral therapy in reducing morbidity and mortality associated with HIV/AIDS.^[@ref2]^ However, the greatest challenge for sub-Saharan Africa has been that most HIV-infected patients present late for ARVS thereby increasing the risk of death in spite of the increasing availability of effective treatment.^[@ref2],[@ref6],[@ref7]^ The recent changes in WHO treatment guidelines,^[@ref9],[@ref10]^ recommending treatment initiation at 350-500 cells/µL, were meant to address this challenge in these settings.

Studies that have examined trends in mortality associated with HIV-infection show that mortality while on HAART was substantially higher in sub-Saharan Africa than in developed countries.^[@ref5]^ A study in England and Wales that examined national trends in death rates and the proportion of deaths attributable to AIDS in the era of effective antiretroviral therapy (ART), and associated risk factors associated with an AIDS-related death found that mortality rate among persons diagnosed with HIV infection aged 15-59 years fell from 217 per 10 000 in 1999 to 82 per 10 000 in 2008, with significant declines in all age groups and exposure categories. However, late diagnosis (CD4 count \<350 cells/μL) was the most important predictor of death (OR 10.55; 95%CI: 8.22-13.54).^[@ref11]^ A French cohort study that examined the impact of HAART on mortality in HIV-positive patients found that mortality was significantly associated with older age,^[@ref12]^ CD4+ count less than 100 cells/mm^3^, anemia, poor nutritional status, hepatitis C virus (HCV) infection, and low level of formal education. Another study in Peru, a developing country, assessed the effect of HAART on mortality over a 5 year period and recorded a 9% mortality while on HAART attributed to low CD4 counts (less than 100 cells/mm^3^) at HAART initiation.^[@ref13]^

Some authors have attributed the main causes of high mortality in African HIV patients starting HAART were low CD4 cell counts and co-morbidities especially tuberculosis at HAART initiation.^[@ref2]^ A study that investigated the geographical and temporal distribution of TB-HIV deaths in Africa, in the period from 1991 to 2006,^[@ref6]^ showed that Eastern, Southern, Western, and Middle Africa experienced an upward trend in the number of reported TB-HIV deaths. Eastern Africa was ranked first in absolute upward trend in number of reported TB-HIV deaths, followed by Southern and Western Africa. Uganda and Kenya were categorized as high risk areas for TB-HIV related deaths.^[@ref6]^ In Botswana, the first 633 patients initiated on public HAART were followed for 5 years (2002-2007) and results showed that 86% of all the deaths occurred in the first 12 months. The majority of deaths were due to advanced HIV disease at HAART initiation, with only a small fraction was attributed to ARV-related toxicities.^[@ref7]^

Uganda is ranked among countries with highest HIV burden worldwide, with about 1.5 million people living with HIV/AIDS, about 130,000 new HIV infections each year.^[@ref14]^ However, in spite of more than 10 years of availability of highly active antiretroviral therapy (HAART), there is paucity of data on trends and predictors of mortality in the different geographical areas. In this study, undertaken in four different geographical areas in Uganda, we sought to describe the mortality patterns and predictors in HIV positive patients in the era of HAART.

Materials and Methods {#sec1-2}
=====================

Study design {#sec2-1}
------------

Observational data of HIV positive patients aged 15 years and above obtaining care and treatment from the AIDS support Organization in Uganda between January 2004 and December 2013 were retrieved and analyzed. Electronic data was obtained from 4 HIV clinics located in four different geographical areas of Uganda. Annual mortality was assessed and results expressed as a percent of HIV positive patients reported dead out of the total number in care per year. Calendar period was used as a proxy measure of HAART exposure.

Settings {#sec2-2}
--------

Data for the study were obtained from TASO, one of the oldest and largest HIV/AIDS care and treatment program in Uganda and sub-saharan Africa. TASO has 11 HIV/AIDS care and treatment centers of excellence (CoE) spread across Uganda. These centers offer comprehensive HIV treatment and care, including pediatric, adolescent and adult HIV care and treatment. TASO HAART program started as part of the National HAART roll-out program in public health facilities in 2004. Being one of the largest HAART providers in the country, TASO attracted a lot of support from different funders supporting HAART programs in sub-Saharan Africa including the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. Initially, HAART eligibility was based on WHO 2006 guidelines *i.e*. WHO stage 3 or 4 illness or a CD4 cell count \<200 cells/μL for adults and adolescents and WHO stage III, advanced stage II or stage I with CD4 cell percentage less than 20% for those more than 18 months of age.^[@ref15]^ However, in 2010 new HAART guidelines,^[@ref9]^ that raised the threshold for adults and adolescents to a CD4 cell count ≤350 or WHO clinical stage 3 or 4 irrespective of CD4 cell count, were adopted.^[@ref16]^ Those who were not eligible for HAART were offered cotrimoxazole prophylaxis. Given the resource constraints and pressing clinical needs, HIV patients could be initiated on HAART basing on clinical presentation without CD4 evaluations. The TASO HAART program has a robust community counseling and social support component including provider initiated and voluntary HIV testing and counseling, distribution of nutritional supplements, monitoring adherence to ART, assessing general clinical conditions of their clients and reporting those severely ill or dead. All services are free of charge including anti-retroviral drugs (ARVs) for those who are eligible.^[@ref17]^

Sampling and sample size {#sec2-3}
------------------------

Four TASO HIV clinics were purposively selected basing on volume, quality of data and geographical representation. The HIV clinics selected were TASO Mulago HIV clinic in central Uganda, TASO Mbarara HIV clinic in south-western Uganda, TASO Tororo HIV clinic in Eastern Uganda and TASO Gulu HIV clinic in Northern Uganda. All HIV positive adults (15 years and above) who attended at least once at the selected HIV clinics in the period from 1^st^ January 2004 to 31^st^ December 2013 were included in the study.

Data collection {#sec2-4}
---------------

Data collection procedure was according to an established protocol across all TASO HIV clinics. In brief, each client is expected to attend the clinic at least once a month. At each clinic visit, data per client is collected on a standardized case report form (CRF) detailing the client's demographic characteristics, clinical condition, medical history, prophylaxis use, OI diagnosis and treatment given. Mortality data was collected using standardized death notification forms. The information was then compiled and entered into the TASO electronic data base using EPIINFO vs3 in Access format. Data for the study were extracted by Data mangers at the study clinics, delinked from overt identifiers and then handed over for analysis.

Statistical analysis {#sec2-5}
--------------------

Statistical analysis was undertaken using Stata 13 (Stata Corp, Collage station, TX, USA). Descriptive statistics were presented as frequencies for categorical data and median with interquartile range (IQR) for numeric data. Differences in variables were tested using chi-squared test or Wilcoxon rank-sum test as appropriate. A time plot of the proportion of HIV positive patients reported dead each year was used to describe the trends. The significance of the trends were tested using X^2^-trend. Logistic regression was used to determine predictors of mortality at univariate and multivariate level respectively. Variables showing significant association in univariate analysis were included in multivariate logistic regression to calculate adjusted odds ratios with 95% confidence intervals. All significance tests were two sided and a P-value \<0.05 was considered significant.

Ethical clearance {#sec2-6}
-----------------

The study obtained ethical clearance from Makerere University School of Public Health Higher Degrees Research and Ethics committee and the Uganda National Council for Science and Technology. Informed consent from study participants was not required as this was routinely collected operational data and the above ethical committees waived the need for consent. However, written consent was obtained from TASO for conducting study and publication of findings with any accompanying images.

Results {#sec1-3}
=======

A total of 95,857 HIV-positive patients were included in the analysis; 64% were female with median age of 33 years (IQR, 27-40). Most of them had primary or no formal education (77%), and without formal employment (living as subsistence farmers or self employed petty trade vendors, 76%) ([Table 1](#table001){ref-type="table"}).

Overall HAART coverage increased from 3% (709/23,577) in 2004 to 74% (22,964/31,173) in 2013 ([Table 2](#table002){ref-type="table"}). The proportion of men accessing HAART was relatively lower compared to women though out the study period *i.e.* only 30% in 2004 and 37% in 2013 ([Table 3](#table003){ref-type="table"}).

At the commencement of HAART, significant differences were observed between male and female ART clients with men being older (median age 35 yrs, IQR 29-42 *vs* 32 yrs IQR 26-39, P\<0.0001) and likely to be more severely ill (WHO clinical stage III and IV 36% *vs* 33%, P\<0.0001) ([Table 3](#table003){ref-type="table"}). The most prescribed HAART regimen was a combination of zidovudine, lamivudine with nevirapine or efavirenz (ZDV+3TC+NVP/EFV) (54%). The median age at the start of HAART was 33 years (IQR 27-40). The median CD4 cell count at the start of HAART in the period 2004-2008 was 195 (IQR 87-328) and 263 (IQR, 146-370) in the period 2009-2013 ([Table 3](#table003){ref-type="table"}).

From 2004 to 2013, a total of 4279 (4.5%) died, among them 2477(58%) were female and 1789 (42%) were male; 19.5% (835/4279) of those who died had an OI. Mortality first increased in early stages of HAART (calendar period 2004-2008) and thereafter substantially declined (X^2^~trend~=211.9, P\<0.001). Overall the proportion of HIV positive patients who died slightly increased from around 5% in 2004 to 6% in 2006-7, then consistently declined up to around 2% in 2013 (X^2^ ~trend~=211.9, P\<0.001). Mortality was highest at Tororo HIV clinic (Eastern Uganda) in which the proportion of HIV positive patients who died first increased from around 7% in 2004 to 9.6% in 2007 and thereafter reduced to around 4% in 2013 but the trend was marginally significant (X^2^~trend~=0.52, P=0.47) ([Figure 1](#fig001){ref-type="fig"}). Gulu HIV clinic (Northern Uganda) recorded the highest mortality in 2004 at about 8% which thereafter reduced consistently to around 2% in 2013(X^2^~trend~=210.2, P\<0.001). At Mbarara HIV clinic (South-western Uganda), the proportion of HIV positive patients who died slightly increased from around 4% in 2004 to 5% in 2006, but thereafter consistently declined up to around 2% in 2013 (X^2^~trend~=15.0, P=0.0001). Mortality was relatively lower at Mulago HIV clinic (Central Uganda) with the proportion reported dead slightly increased from 3% in 2004 to 4.3% in 2006 and thereafter consistently declined to 0.7% in 2013 (X^2^~trend~=100.2, P\<0.001) ([Figure 1](#fig001){ref-type="fig"}).

In multivariate analysis, the odds of death were significantly higher in male gender with men being 37% more at risk compared to women (OR 1.37, 95%CI 1.26-1.49, P\<0.001). The odds of death were 15% higher in age \>45 years compared to those \<25 year (OR 1.15, 95%CI 1.01-1.33). Patients who were unemployed/subsistence farmers were 28% more likely to die compared to these who are formally employed (OR 1.28, 95%CI 1.15-1.43, P\<0.001). Patients from eastern Uganda were 3 times more likely to die compared to patients from central Uganda (OR 3.18, 95%CI 2.80-3.61 P\<0.001). WHO stage III and IV at HAART initiation increased the odds of death by 77% compared to those in WHO stages I and II (OR 1.77, 95%CI 1.62-1.93, P\<0.001). CD4 count \<100 cells/µL of blood increased the odds of death 3 times compare to patients whose CD4 count was \>350 cells/µL of blood (OR 3.37, 95%CI 2.78-4.09, P\<0.001). Patients with a baseline weight \<45 kg were twice more likely to die compared to patients whose baseline weight was \>60 kg (OR 1.95, 95%CI 1.65-2.31, P\<0.001) and patients who were in care in calendar period 2004-2008 were more likely to die compare to patients who were in care in calendar period 2009-2013 (OR 2.21, 95%CI 2.01-2.41, P\<0.001) ([Table 4](#table004){ref-type="table"}).

Discussion {#sec1-4}
==========

This study gives an insight on trends and predictors of mortality in the HAART era in Uganda. The nature of patients included in the study is almost similar to other HIV positive patients on HAART in resource poor settings. Our results were consistent with those obtained from other previous studies in resource-constrained settings.^[@ref2],[@ref5],[@ref18]^ Mortality first increased in early stages of HAART (calendar period 2004-2008) but later declined consistently attributed to the expanded coverage of HAART.^[@ref21],[@ref22]^ However increasing use of cotrimoxazole prophylaxis and introduction of improved therapeutic drugs (fluconazole, acyclovir, *etc*) could also account for some of the observed decline in mortality over time.^[@ref23]^

In our study, we observed high mortality among those initiated on HAART in WHO clinical stage III and IV or CD4 cell count \<100 cells/µL especially in the period between 2004 and 2008. These results are comparable to other reports from other studies.^[@ref20],[@ref22],[@ref29]^ In our study, mortality was 3 times higher in patients who initiated HAART with CD4 count less or equal to 100 cells/µL compared to those who were initiated on HAART with CD4 above 350 cell/µL. These results are almost similar to those described elsewhere.^[@ref2],[@ref20],[@ref35],[@ref36]^ However, it should also be noted that in Uganda, in spite of availability of free HAART and cotrimoxazole prophylaxis, only 13% of adult women and 11% of adult men ever tested and known their HIV status implying that majority were more likely to present for treatment with advanced HIV disease.^[@ref37]^ In fact, previous studies in Uganda have shown 40% of those eligible for HAART present with late disease stage for treatment resulting into poor prognostic outcomes.^[@ref34],[@ref38],[@ref39]^ In the current study, 19.5% (835/4279) of those who died had an opportunistic infection. Patients with CD4-cell counts \<100 cells/µL were more likely to experience an OI, with men being at higher risk for life threatening OIs such as mycobacterium tuberculosis and cryptococcal meningitis compared to women.

A study in Ivory coast involving a cohort of 792 HIV infected adults found the incidence of mortality and severe morbidity was high among patients whose pre-HAART CD4 count was \<350. These patients reported with severe infections including invasive bacterial diseases (49%) and TB (38%) that increased the risk of death.^[@ref33]^

In our study, male gender was a strong predictor of mortality (OR 1.4; 1.3-1.5). This is consistent with several other previous studies which show gender differences in ART out-comes.^[@ref20],[@ref31],[@ref40],[@ref41]^ However, our findings differ from other studies which found no significant difference in the risk of death between gender.^[@ref2],[@ref5],[@ref19]^ Potential confounders such as gender differences in treatment access and adherence, socio-cultural differences, HIV-related stigma and health seeking behavioral differences could probably explain this gender difference. However some studies have attributed this problem to men's reluctance to go for early HIV testing hence late HAART initiation associated with poor prognostic outcomes.^[@ref8]^ Old age and low weight (proxy indicator for malnutrition) at start of HAART were significant predictors of mortality in our study. Patients with a weight \<45 kg were more than twice at higher risk of death (OR 2.4, 95%CI 2.1-2.8) compared to those above 60 kg at HAART initiation. This is consistent with findings from other studies in resource poor settings.^[@ref2],[@ref19],[@ref31],[@ref42]^ Zachariah and colleagues demonstrated that mortality increased with severity of malnutrition in HIV-infected patients starting HAART in Tanzania. In their study they found 1-year mortality at 46.8% for those with severe malnutrition (BMI \<16 kg/m^2^) compared to only 13.7% mortality in patients with normal nutritional status (BMI ≥18.5 kg/m^2^).^[@ref42]^ This is probably because malnutrition (under nutrition) is associated with poverty increases the risk of anemia, compromises immunity and therefore undermines the effectiveness of HAART resulting in increased the risk of OIs and death.^[@ref43]^ Older age (\>45 yrs) was strongly associated with mortality OR 1.30 (1.17-1.44) compared to younger age (\<25 yrs) which is also consistent with previous studies.^[@ref31]^ A study in Uganda found that a large percentage of elderly persons (33.3%) were malnourished.^[@ref44]^ The risk of death was also strongly associated with calendar period consistent with a previous study which assessed ART outcomes in African and Asian HIV programs.^[@ref31]^ In the early year of HAART, the focus were the severely ill HIV positive patients (CD4 cell count \<200 cells/µL) while in later years of HAART the threshold for HAART eligibility changed to include even those with CD4 cell count of up to 350 cell/µL.^[@ref9]^ However increase in mortality observed between 2004 and 2006 could be due to poor mortality data collection in the early years HAART and which may have improved in the later years.

Having no education or only primary education was a strong predictor of mortality among HIV patients in Uganda. The odds of death were 1.47 (95%CI 1.21-1.78) higher in patients with no formal education and 1.38 (95%CI 1.14-1.60) higher in patients with only primary education compared to those with tertiary education. Our findings are consistent with those got from other previous studies.^[@ref45],[@ref46]^ However differed from another study that found no association of education with mortality in Tanzania.^[@ref35]^

In our study, the odds of death were worse if a patient was from eastern Uganda (OR 3.6, 95%CI 3.3-4.0, P\<0.001) or northern Uganda (OR 2.1, 95%CI 1.9-2.3, P\<0.001) which is consistent with other studies that also found geographical variation in HAART effect on mortality.^[@ref5]^ Geographical location may be related to timely access to quality health care as most rural centers have clients who have to travel long distances to access services involving high transport costs. Very little is known about the role of religion in mortality among HIV patients. In our study we found the odds of death were higher among Catholics (OR 1.3, 95%CI 1.1-1.5) and Protestants (OR 1.2, 95%CI 1.0-1.4) compared to Born-again/Pentecostal Christians. This difference could probably be explained by behavioral lifestyles.^[@ref35]^ Patients who were unemployed/subsistence farmers had a higher risk of death (OR 1.4, 95%CI 1.3-1.5) compared to the employed. This finding is consistent with studies elsewhere in which it was shown that lack of education or unemployment were strongly associated with poverty and hence poor prognostic outcomes on HAART.^[@ref13],[@ref35],[@ref46]^

Limitations {#sec2-7}
-----------

This study had a number of limitations. First we were not able to determine the exact cause of deaths, and to attribute all of them to HIV could over estimate HIV-related mortality. Secondly, the data were collected for operational purposes and so to a certain degree may have underreported some of the events. For example our analysis was limited to the mortality data captured in the TASO data base which probably under-estimates the true mortality risk, given the fact that many deaths may have never been reported especially among those who transferred out of program care. Another limitation was that the role of adherence to HAART was not assessed especially among the unemployed/peasant farmers who had a relatively higher risk of death compared to those who were employed aware that poor adherence to HAART may result into poor prognostic outcomes.^[@ref47],[@ref48]^ However this may not necessarily be the reason given that previous studies in the same settings reported 78-86% had good adherence to HAART (\>95%).^[@ref34],[@ref49]^ Nevertheless, the study provides additional evidence of a significant impact of HAART on mortality despite the above limitations.

Conclusions {#sec1-5}
===========

This was rather a long observational study (10 years) that reflects the operational realities in most resource poor settings. HAART coverage in these settings has substantially increased by over 70% since HAART roll out in 2004. Increased HAART coverage has significantly altered mortality trends from increasing to declining trends in all the regions of Uganda studied. Fewer men than women were on HAART (34%) and the hazards of death were greater in men compared to women (OR 1.4; 95%CI 1.3-1.5) providing additional evidence of an going challenge of men performance while on HAART. Mortality trends differed significantly by geographical area and male gender, older age (\>45 years), being from Eastern or Northern Uganda, low levels of education, being unemployed, advanced immunodeficiency (CD4 count \<100 cell/µL) or WHO stage III or IV) and malnutrition (\<45 kg weight) at HAART initiation were significant predictors of mortality in these settings. This therefore calls for targeted interventions for those highly at risk of death. There is urgent need for men targeted interventions for improved art performed.

The authors are grateful to the AIDS Support Organization (TASO) in Uganda for providing the data for the study. We would also like to extend our sincere appreciation to Mountains of the Moon University for the financial support.
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###### 

Demographic characteristics of the study participants, total and clinic-specific.

  Variable                       Total number, n (%)   Tororo HIV clinic, n (%)   Mulago HIV clinic, n (%)   Mbarara HIV clinic, n (%)   Gulu HIV clinic, n (%)   P[\*](#table001-tfn1){ref-type="table-fn"}
  ------------------------------ --------------------- -------------------------- -------------------------- --------------------------- ------------------------ --------------------------------------------
  Gender, F (n=95,857)           61,030(64)            14,435(62)                 18,689(66)                 15,972(63)                  11,934(62)               \<0.001
  Age (n=94,368), median (IQR)   33 (27.40)            34 (28.42)                 33 (27.40)                 33 (27.40)                  33 (26.40)               \<0.001
        \<25yrs                  16,272(17)            3445(15)                   5139(18)                   4194(17)                    3494(19)                 
        25-34yrs                 35,199(37)            8077(35)                   10,589(38)                 9853(39)                    6680(37)                 
        35-44yrs                 28,293(30)            7306(32)                   8251(29)                   7635(30)                    5101(28)                 
        45yrs and above          14,613(16)            4215(18)                   4093(15)                   3544(14)                    2761(15)                 
  Occupation (n=83,084)                                                                                                                                           \<0.001
        Paid employee            14,529(17)            2249(11)                   6378(27)                   2720(13)                    3182(18)                 
        Petty trade vendor       29,890(36)            6589(32)                   10,437(46)                 5187(24)                    7677(43)                 
        Peasant                  33,506(40)            10,953(52)                 4257(18)                   12,007(56)                  6289(35)                 
        Others                   5159(6)               1048(5)                    2016(9)                    1322 (7                     773(4)                   
  Education (n=85,957)                                                                                                                                            \<0.001
        None                     18,250(21)            5761(28)                   2585(11)                   5131(21)                    4773(27)                 
        Primary                  48,063(56)            11,397(54)                 12,620(55)                 14,228(58)                  9818(55)                 
        Secondary                16,347(19)            3095(15)                   6541(28)                   3972(17)                    2739(15)                 
        Tertiary or above        3297(4)               616(3)                     1309(6)                    791(3)                      581(3)                   
  Marital status (86,137)                                                                                                                                         \<0.001
        Single/never married     5338(6)               1474(7)                    1609(7)                    1563(6)                     692(4)                   
        Married/cohabiting       40,689(47)            11,271(54)                 9832(43)                   11,097(46)                  8489(47)                 
        Divorced                 16,058(19)            2679(13)                   6182(27)                   4053(17)                    3144(17)                 
        Widowed                  19,797(23)            4729(23)                   4459(19)                   6108(25)                    4501(25)                 
        Others                   4255(5)               686(3)                     968(4)                     1473(6)                     1128(6)                  
  Religion/faith (n=85,256)                                                                                                                                       \<0.001
        Catholic                 39,508(46)            8816(42)                   8690(38)                   9025(38)                    12,977(73)               
        Protestant               29,807(34)            6898(33)                   8690(34)                   11,923(51)                  3073(17)                 
        Muslim                   6621(8)               1692(8)                    3160(14)                   1310(6)                     459(3)                   
        Pentecostal              6635(8)               2358(11)                   2454(11)                   838(3)                      985(5)                   
        Others                   2685(3)               1064(5)                    795(3)                     508(2)                      318(2)                   

\*Chi-squared or Mann Whitney test.

###### 

Number of study participants accessing highly active antiretroviral therapy (ART) in the period 2004 to 2013, total and clinic-specific.

  Year   Gulu HIV clinic   Mulago HIV clinic   Mbarara HIV clinic   Tororo HIV clinic   All sites                                                
  ------ ----------------- ------------------- -------------------- ------------------- ----------- ------------- ------- ------------- -------- ---------------
  2004   2895              13 (0.4)            6292                 363 (5.8)           8121        125 (1.5)     6269    208 (3.3)     23,577   709 (3.0)
  2005   4625              349 (7.5)           596                  936 (15.7)          5837        978 (16.8)    6491    463 (7.1)     22,913   2726 (11.9)
  2006   4938              569 (11.5)          5174                 1066 (20.6)         5984        1030 (17.2)   54      491 (9.1)     21,496   3156 (14.7)
  2007   5260              1338 (25.4)         5332                 1700 (31.9)         6632        2182 (32.9)   6723    1015 (15.1)   23,947   6235 (26.0)
  2008   5739              1836 (32.0)         5802                 2111 (36.4)         682         2124 (31.1)   8221    1972 (24.0)   26,582   8043 (30.2)
  2009   7291              2695 (37.0)         6466                 2571 (33.6)         7382        2756 (37.3)   9893    2813 (28.4)   31,032   10,835 (34.9)
  2010   7266              2927 (40.3)         8012                 3155 (39.4)         756         2982 (39.4)   10613   4304 (40.5)   33,451   13,368 (40.0)
  2011   7967              4256 (53.4)         9297                 4247 (45.7)         9262        3891 (42.0)   9733    5277 (54.2)   36,259   17,671 (48.7)
  2012   8389              5051 (60.2)         9728                 4669 (48.0)         9789        4558 (46.6)   8333    6452 (77.4)   36,236   20,730 (57.2)
  2013   8361              5789 (69.2)         7493                 5787 (77.2)         7199        4707 (65.4)   8122    6681 (82.3)   31,175   22,964 (73.7)

###### 

Baseline characteristics of the study participants at commencement of highly active antiretroviral therapy (ART), total and gender specific (N=36,372).

  Characteristic                               Total           Female          Male            P[\*](#table003-tfn1){ref-type="table-fn"}
  -------------------------------------------- --------------- --------------- --------------- --------------------------------------------
  Age, median (interquartile range)            33 (27.40)      32 (26.39)      35 (29.42)      \<0.001
  WHO stage, III & IV, n (%)                   30,185(34)      18,793(33)      11,392(36)      \<0.001
  CD4 cells/µL, median (interquartile range)                                                   
        2004-2008                              195 (87,328)    195 (87,334)    194 (87,318)    \<0.001
        2009-2013                              263 (146,370)   273 (159,377)   244 (123,354)   \<0.001
  ART regimen (2005-2013), n (%)                                                               \<0.001
        d4T + 3TC+ NVP/EFV                     6728(9)         4874(9)         1854(7)         
        ZDV+3TC+NVP/EFV                        40,784(54)      27,408(54)      13,376(53)      
        TDF+FTC+LPV/r                          16,218(21)      10495(21)       5723(23)        
        TDF+3TC+NVP/EFV                        5350(7)         3472(7)         1878(7)         
        Others                                 7120(9)         4789(9)         2331(9)         
  Median weight, kg (interquartile range)      54 (47.61)      54 (47.61)      55 (49.62)      \<0.001
  Calendar year of ART initiation                                                              \<0.001
        2004                                   592(2)          415(70)         177(30)         
        2005                                   2870(8)         2035(71)        835(29)         
        2006                                   1965(5)         1315(67)        650(33)         
        2007                                   3789(10)        2483(66)        1306(34)        
        2008                                   2560(7)         1675(65)        885(35)         
        2009                                   4549(12)        2972(65)        1573(35)        
        2010                                   5341(15)        3484(65)        1857(35)        
        2011                                   4116(11)        2631(64)        1485(36)        
        2012                                   6449(18)        4157(64)        2292(36)        
        2013                                   4145(11)        2600(63)        1545(37)        

\*Chi-squared test.

###### 

Factors associated with mortality among HIV+ individuals from 4 different geographical areas in Uganda, Odds Ratio (OR, 95%CI).

  Patient factor                                      Not at risk   Died, n (%)   Crude OR ratio     P         Adjusted OR[\*](#table004-tfn1){ref-type="table-fn"}   P
  --------------------------------------------------- ------------- ------------- ------------------ --------- ------------------------------------------------------ ---------
  Sex                                                                                                                                                                 
        Female                                        61,031        2477 (4.1)    1                            1                                                      
        Male                                          32,583        1789 (5.5)    1.37 (1.29-1.46)   \<0.001   1.37 (1.26-1.49)                                       \<0.001
        Not recorded                                  2244          13 (0.58)     0.14 (0.08-0.24)   \<0.001   0.19 (0.17-0.71)                                       0.053
  Age                                                                                                                                                                 
        \<25yrs                                       16,235        684 (4.2)     1                            1                                                      
        25-34                                         35,193        1474 (4.2)    0.99 (0.90-1.09)   0.896     1.03 (0.91-1.16)                                       0.666
        35-44                                         28,272        1318 (4.7)    1.11 (1.01-1.22)   0.028     1.04 (0.92-1.18)                                       0.491
        ≥45                                           14,592        790 (5.4)     1.30 (1.17-1.44)   \<0.001   1.15 (1.01-1.33)                                       0.038
        Not recorded                                  1566          13 (0.8)      0.19 (0.11-0.33)   \<0.001   2.82 (0.65-12.33)                                      0.167
  Geographical location                                                                                                                                               
        Central                                       28,353        638 (2.2)     1                            1                                                      
        Eastern                                       23,126        1779 (7.7)    3.62 (3.30-3.97)   \<0.001   3.18 (2.80-3.61)                                       \<0.001
        Western                                       25,268        990 (3.9)     1.77 (1.60-1.96)   \<0.001   1.81 (1.58-2.07)                                       \<0.001
        Northern                                      19,111        872 (4.6)     2.08 (1.87-2.30)   \<0.001   1.46 (1.26-1.68)                                       \<0.001
  Education                                                                                                                                                           
        None                                          18,250        952 (5.2)     1.47 (1.21-1.78)   \<0.001   0.94 (0.73-1.21)                                       0.629
        Primary                                       48,064        2357 (4.9)    1.38 (1.14-1.66)   \<0.001   0.96 (0.78-1.26)                                       0.975
        Secondary                                     16,347        654 (4.0)     1.11 (0.91-1.36)   0.292     0.89 (0.69-1.14)                                       0.359
        Tertiary                                      3297          119 (3.6)     1                            1                                                      
        Not recorded                                  9900          197 (2.0)     0.54 (0.43-0.68)   \<0.001   0.59 (0.41-0.85)                                       0.004
  Religion/Faith                                                                                                                                                      
        Pentecostal                                   6635          261 (3.9)     1                                                                                   
        Protestant                                    29,807        1390 (4.7)    1.20 (1.04-1.37)   0.0098                                                           
        Muslim                                        6621          288 (4.3)     1.11 (0.93-1.32)   0.229                                                            
        Catholic                                      39,508        1984 (5.0)    1.30 (1.13-1.47)   0.0001                                                           
        Others                                        2686          130 (4.8)     1.24 (1.00-1.54)   0.048                                                            
        Not recorded                                  10,601        226 (2.1)     0.53 (0.44-0.64)   \<0.001                                                          
  Occupation                                                                                                                                                          
        Formally employed                             14,529        528 (3.6)     1                            1                                                      
        Unemployed/self employed/subsistence farmer   68556         3428 (5.0)    1.39 (1.27-1.53)   \<0.001   1.28 (1.15-1.43)                                       \<0.001
        Not recorded                                  12,773        323 (2.1)     0.69 (0.60-0.79)   \<0.001   0.87 (0.75-1.01)                                       0.072
  Marital status                                                                                                                                                      
        Single/never married                          5338          272 (5.1)     1                                                                                   
        Married/cohabiting                            40,689        2036 (5.0)    0.98 (0.86-1.12)   0.773                                                            
        Divorced                                      16,058        707 (4.4)     0.86 (0.74-0.99)   0.036                                                            
        Widowed                                       19,798        835 (4.2)     0.82 (0.71-0.94)   0.005                                                            
        Others                                        4255          234 (5.5)     1.08 (0.91-1.30)   0.379                                                            
        Not recorded                                  9720          195 (2.0)     0.38 (0.32-0.46)   \<0.001                                                          
  WHO stage at start of ART                                                                                                                                           
        I&II                                          24,337        1516 (6.2)    1                                                                                   
        III&IV                                        10,716        1068(10)      1.67 (1.53-1.81)   \<0.001   1.77 (1.62-1.93)                                       \<0.001
        Not recorded                                  1319          210 (15.9)    2.85 (2.44-3.33)   \<0.001   1.82 (1.54-2.15)                                       \<0.001
  CD4 cell count at start of ART                                                                                                                                      
        0-100                                         3824          524 (13.7)    3.12 (2.58-3.77)   \<0.001   3.37 (2.78-4.09)                                       \<0.001
        101-350                                       9372          601 (6.4)     1.35 (1.12-1.61)   \<0.001   1.47 (1.22-1.76)                                       \<0.001
        \>350                                         3158          153 (4.8)     1                            1                                                      
        Not recorded                                  20,018        1516 (7.6)    1.61 (1.36-1.91)   \<0.001   1.94 (1.62-2.32)                                       \<0.001
  Weight at start of ART                                                                                                                                              
        \<45kg                                        4010          420 (10.5)    2.44 (2.08-2.86)   \<0.001   1.95 (1.65-2.31)                                       \<0.001
        45-60kg                                       13,876        925 (6.7)     1.49 (1.29-1.71)   \<0.001   1.26 (1.09-1.45)                                       \<0.001
        \>60kg                                        5745          263 (4.6)     1                            1                                                      
        Not recorded                                  12,741        1186 (9.3)    2.14 (1.86-2.46)   \<0.001   1.51 (1.31-1.74)                                       \<0.001
  Calendar period                                                                                                                                                     
        2004-2008                                     58,832        3081 (5.2)    1.65 (1.54-1.77)   \<0.001   2.21 (2.01-2.41)                                       \<0.001
        2009-2013                                     37,026        1198 (3.2)    1                            1                                                      

OR, odds ratio; CI, confidence interval.

\*Adjusted ORs for calendar period after controlling for sex, geographical location, occupation, baseline CD4 count and baseline weight of individual HIV positive patients.
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